New Hope for Alzheimer’s Patients Cerevance recently announced promising results from its Phase 3 ARISE clinical trial, marking a potential turning point in the treatment of Alzheimer’s disease. The study evaluated the efficacy and safety of solengepras, a novel once-daily oral medication designed to address the progression of cognitive decline. Meeting Primary Endpoints The ARISE…